Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 12/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8382438 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL10758036 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL10757502 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL1795959 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL7843902 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL20969262 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL11179206 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL1793039 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL7756737 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL1795960 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102060796-A | Method for preparing amphiphilic triazine compounds by continuous one-pot method | UNIV FUJIAN | 2011-05-18 | — | — | CN | claimed |
| CN-115141102-A | Latent heat storage material, latent heat storage body, electronic device, and electricity storage device | K-材料研究室股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-110382453-A | The manufacturing method of (methyl) acrylate | 东亚合成株式会社 | 2019-10-25 | — | — | CN | disclosed |
| CN-104254906-B | The processing method of semiconductor substrate cleaning agent and semiconductor substrate surface | 和光纯药工业株式会社 | 2017-07-21 | — | — | CN | disclosed |
| CN-104254906-A | Cleaning agent for semiconductor substrates and method for processing semiconductor substrate surface | WAKO PURE CHEM IND LTD | 2014-12-31 | — | — | CN | disclosed |
| CN-102060796-A | Method for preparing amphiphilic triazine compounds by continuous one-pot method | UNIV FUJIAN | 2011-05-18 | — | — | CN | disclosed |
| EP-1852506-A2 | Lipophilic derivatives of double-stranded ribonucleic acid | Alnylam Europe AG (DE) | 2007-11-07 | — | — | EP | disclosed |
| EP-1587926-B1 | LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID | ALNYLAM EUROPE AG (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060178324-A1 | Lipophilic derivatives of double-stranded ribonucleic acid | ALNYLAM PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1587926-A2 | LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID | Alnylam Europe AG (DE) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004065601-A2 | LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID | ALNYLAM EUROPE AG (DE) | 2004-08-05 | — | — | WO | disclosed |
| US-4397965-A | HYDRAZINE DERIVATIVE BLOWING AGENT | UNIROYAL, INC. (US) | 1983-08-09 | — | — | US | disclosed |
| EP-0083173-A1 | Expandable and curable polyester composition and method for making same | UNIROYAL, INC. (US) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178324-A1 | Lipophilic derivatives of double-stranded ribonucleic acid | RNASE1, POLRMT, SNRPE | DNM1 672/4885TSHR 3089/4885THRB 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.